Summary:
- Kyowa Kirin, a global specialty pharmaceutical company, has decided to regain control of the development and commercialization of rocatinlimab, a potential treatment for atopic dermatitis (a chronic, inflammatory skin condition).
- Atopic dermatitis is a common skin condition that causes red, itchy, and inflamed skin, and it can significantly impact a person's quality of life. Rocatinlimab is a promising new treatment that Kyowa Kirin believes can address this high unmet medical need.
- By taking back control of the rocatinlimab program, Kyowa Kirin is demonstrating its strong commitment to developing and bringing this new treatment option to patients with atopic dermatitis, which can be a difficult condition to manage.